Lytham Partners, a leading investor relations firm, today announced the schedule for its Fall 2024 Investor Conference taking ...

MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 ...

Check the time stamp on this data. Updated AI-Generated Signals for Mannkind Corporation (MNKD) available here: MNKD.

Discover MannKind Corp's innovative patent for synthesizing N-protected 3,6-aminoalkyl-2,5-diketopiperazines, enhancing organic chemistry and pharmaceutical advancements.

On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.6 which represents a decrease of $-0.10 or -1.49% from the prior close of $6.7. The stock opened at $6.7 and touched a low of ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

Sept. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients ...

MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.66 which represents a slight increase of $0.10 or 1.52% from the prior close of $6.56. The stock opened at $6.61 and touched a low ...

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung ...

The volatility ratio for the week is 4.32%, and the volatility levels for the last 30 days are 4.91% for Mannkind Corp . The simple moving average for the past 20 days is 13.00% for MNKD’s stock, with ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...